• Stoke Therapeutics posted Q2 net loss of USD 61.6 million, or USD 0.93 a share, widening from a USD 23.5 million loss.
• Revenue fell 32.52% to USD 9.33 million; R&D expenses climbed 91.45% to USD 49.5 million.
• SG&A costs increased 65.29% to USD 25.25 million, driven by growth in personnel and launch readiness expenses.
• Cash, cash equivalents and marketable securities totaled USD 420 million, expected to fund operations through potential U.S. commercialization in early 2028.
• Phase 3 EMPEROR enrollment of 162 zorevunersen patients is complete; Phase 3 data are expected in Q3 2027, with rolling U.S. NDA start planned in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608031601BIZWIRE_USPR_____20260803_BW082079) on August 03, 2026, and is solely responsible for the information contained therein.